Detail akcie Akebia Therapeutics online

Business Summary: Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Akebia Therapeutics Inc revenues increased 47% to $236.2M. Net loss decreased 92% to $5.3M. Revenues reflect Product revenue, net increase of 49% to $227.3M, License, collaboration and other revenue increase of 11% to $8.9M. Lower net loss reflects Development and commercialization segment income totaling $23.5M vs. loss of $50.5M.